MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.380
+0.020 (1.47%)
Mar 9, 2026, 4:00 PM EDT - Market closed
MediciNova Revenue
In the year 2025, MediciNova had annual revenue of $409.66K. MediciNova had revenue of $151.74K in the quarter ending December 31, 2025.
Revenue (ttm)
$409.66K
Revenue Growth
n/a
P/S Ratio
165.81
Revenue / Employee
$31,512
Employees
13
Market Cap
67.93M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TScan Therapeutics | 10.33M |
| ImageneBio | 800.00K |
| Spruce Biosciences | 697.00K |
| Coeptis Therapeutics Holdings | 501.00K |
| InflaRx | 73.73K |
| Impact BioMedical | 25.00K |
MNOV News
- 5 weeks ago - MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - GlobeNewsWire
- 2 months ago - 2026 New Year's Greetings from the CEO - GlobeNewsWire
- 2 months ago - MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy - GlobeNewsWire
- 3 months ago - MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - GlobeNewsWire
- 3 months ago - MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor - GlobeNewsWire
- 4 months ago - MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards - GlobeNewsWire
- 4 months ago - MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication - GlobeNewsWire
- 5 months ago - MediciNova to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire